Nitto Denko
NEW YORK (GenomeWeb) – Japan's Nitto Denko announced this month that it has initiated a Phase Ib study of its siRNA-based fibrosis treatment ND-L02-s0201, just months after the drug successfully completed a Phase Ia safety study in healthy volunteers.
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
Title: Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis
Patent Number: 8,652,526
Filed: April 4, 2012
Title: Therapeutic Agent for Pulmonary Fibrosis
Patent Number: 8,574,623
Filed: Oct. 10, 2012
Lead Inventor: Yoshiro Niitsu, Nitto Denko
IP Update: Recent Patents, Patent Applications Awarded to Rosetta, Nitto Denko, Merck, and More
Premium
Title: Nucleic Acids Involved in Viral Infection
Patent Number: 8,481,506
Filed: Dec. 5, 2007
Lead Inventor: Isaac Bentwich, Rosetta Genomics
Jun 6, 2013
Jun 6, 2013
Feb 10, 2011
Feb 3, 2011
Aug 5, 2010
Jul 22, 2010
Jul 15, 2010